1. Home
  2. ITOS vs NBH Comparison

ITOS vs NBH Comparison

Compare ITOS & NBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • NBH
  • Stock Information
  • Founded
  • ITOS 2011
  • NBH 2002
  • Country
  • ITOS United States
  • NBH United States
  • Employees
  • ITOS N/A
  • NBH N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • NBH Finance/Investors Services
  • Sector
  • ITOS Health Care
  • NBH Finance
  • Exchange
  • ITOS Nasdaq
  • NBH Nasdaq
  • Market Cap
  • ITOS 270.7M
  • NBH 288.5M
  • IPO Year
  • ITOS 2020
  • NBH N/A
  • Fundamental
  • Price
  • ITOS $6.67
  • NBH $10.13
  • Analyst Decision
  • ITOS Strong Buy
  • NBH
  • Analyst Count
  • ITOS 3
  • NBH 0
  • Target Price
  • ITOS $25.67
  • NBH N/A
  • AVG Volume (30 Days)
  • ITOS 550.0K
  • NBH 85.9K
  • Earning Date
  • ITOS 04-28-2025
  • NBH 01-01-0001
  • Dividend Yield
  • ITOS N/A
  • NBH 4.34%
  • EPS Growth
  • ITOS N/A
  • NBH N/A
  • EPS
  • ITOS N/A
  • NBH 0.12
  • Revenue
  • ITOS $35,000,000.00
  • NBH N/A
  • Revenue This Year
  • ITOS N/A
  • NBH N/A
  • Revenue Next Year
  • ITOS $31.74
  • NBH N/A
  • P/E Ratio
  • ITOS N/A
  • NBH $87.04
  • Revenue Growth
  • ITOS 177.89
  • NBH N/A
  • 52 Week Low
  • ITOS $4.80
  • NBH $8.75
  • 52 Week High
  • ITOS $18.75
  • NBH $11.01
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 49.00
  • NBH 50.31
  • Support Level
  • ITOS $6.18
  • NBH $10.09
  • Resistance Level
  • ITOS $7.80
  • NBH $10.23
  • Average True Range (ATR)
  • ITOS 0.50
  • NBH 0.10
  • MACD
  • ITOS -0.05
  • NBH 0.03
  • Stochastic Oscillator
  • ITOS 29.94
  • NBH 76.07

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About NBH Neuberger Berman Municipal Fund Inc.

Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.

Share on Social Networks: